Claims
- 1. A method for treating patients with liver diseases comprising:
co-administering to said patients an effective amount of a pharmaceutical composition and lamivudine, wherein said pharmaceutical composition comprises aqueous extracts of an entire plant of Herba Hedyotidis diffusae, a rhizome of Rhizoma Bistortae, a rhizome of Rhizoma Polygoni Cuspidati, and a ripe fruit of Fructus Schisandrae.
- 2. The method according to claim 1, said pharmaceutical composition further comprising aqueous extracts of a rhizome of Rhizoma Menispermi, a root of Radix Scutellariae, a bovine biliary powder, a tuber of Radix Curcumae, a ripe fruit of Fructus Crataegi, and a root of Radix Notoginseng.
- 3. The method according to claim 2, further comprising aqueous extracts of a ripe fruit of Fructus Lycii, a root of Radix Ginseng Rubra, a root of Radix Scorphulariae, a root of Radix Angelicae sinensis, and a root of Radix Astragali.
- 4. The method according to claim 3, wherein said pharmaceutical composition is administered to said patients orally.
- 5. The method according to claim 4, wherein said orally administered pharmaceutical composition is in a dosage amount of about 0.5 to 5 g of said aqueous extracts of said pharmaceutical composition per day per person.
- 6. The method according to claim 5, wherein said dosage amount of said orally administered pharmaceutical composition is about 1 to 3 g of said aqueous extracts of said pharmaceutical composition per day per person.
- 7. The method according to claim 3, wherein said pharmaceutical composition is administered by intravenous injection.
- 8. The method according to claim 7, wherein said pharmaceutical composition is in a dosage amount of about 1 to 10 g of said pharmaceutical composition per day per person.
- 9. The method according to claim 8, wherein the dosage amount of said pharmaceutical composition is about 3-5 g of said pharmaceutical composition per day per person.
- 10. The method according to claim 3, wherein said pharmaceutical composition is concurrently administered orally and intravenously.
- 11. The method according to claim 1, wherein said lamivudine is administered orally.
- 12. The method according to claim 1, wherein said lamivudine is orally administered in a dosage amount of 50-500 mg per day per person.
- 13. The method according to claim 12, wherein the dosage amount of said lamivudine is about 100 to 200 mg per day per person.
- 14. The method according to claim 1, wherein said liver diseases comprises at least one which is selected from the group consisting of hepatitis, cirrhosis, and liver cancer.
- 15. The method according to claim 1, wherein said liver diseases are caused by hepatitis B viral (HBV) infection.
- 16. A pharmaceutical combination comprising a first dosage unit of said pharmaceutical composition of claim 3 and a second dosage unit of lamivudine.
- 17. The pharmaceutical combination according to claim 16, wherein said first dosage unit of said pharmaceutical composition is at least one which is selected from the group consisting of oral dosage form of said pharmaceutical composition and intravenous injection solution of said pharmaceutical composition.
- 18. The pharmaceutical combination according to claim 17, wherein said oral dosage form of said pharmaceutical composition is at the amount of about 0.1 to 2 g per administration and at about 2-4 times a day.
- 19. The pharmaceutical combination according to claim 17, wherein said intravenous injection solution of said pharmaceutical composition is at the amount of about 1 to 10 g per administration and at about once a day.
- 20. The pharmaceutical combination according to claim 16, wherein said lamivudine is about 50 to 500 mg per administration and at about once a day.
- 21. The pharmaceutical combination according to claim 16, wherein said pharmaceutical composition is used to treat patients with liver diseases.
- 22. The pharmaceutical combination according to claim 16, wherein said liver diseases are at least one selected from the group consisting of hepatitis, cirrhosis, and liver cancer.
- 23. The pharmaceutical combination according to claim 22, wherein said liver diseases are caused by hepatitis B viral (HBV) infection.
- 24. A method for preventing a relapse of hepatitis in patients after withdrawal of lamivudine treatment comprising;
administering a pharmaceutical composition to said patients after the withdrawal of lamivudine treatment; wherein said pharmaceutical composition comprises aqueous extracts of an entire plant of Herba Hedyotidis diffusae, a rhizome of Rhizoma Bistortae, a rhizome of Rhizoma Polygoni Cuspidati, and a ripe fruit of Fructus Schisandrae.
- 25. The method according to claim 24, said pharmaceutical composition further comprising aqueous extracts of a rhizome of Rhizoma Menispermi, a root of Radix Scutellariae, a bovine biliary powder, a tuber of Radix Curcumae, a ripe fruit of Fructus Crataegi, and a root of Radix Notoginseng.
- 26. The method according to claim 25, said pharmaceutical composition further comprising aqueous extracts of a ripe fruit of Fructus Lycii, a root of Radix Ginseng Rubra, a root of Radix Scorphulariae, a root of Radix Angelicae sinensis, and a root of Radix Astragali.
- 27. The method according to claim 26, wherein said pharmaceutical composition is administered orally or intravenously, or is concurrently administered orally and intravenously.
- 28. The method according to claim 24, wherein said hepatitis is caused by hepatitis B viral (HBV) infection.
- 29. A method for supressing a development of lamivudine drug resistance in patients comprising:
adminstering a pharmaceutical composition to said patients; wherein said pharmaceutical composition comprises aqueous extracts of an entire plant of Herba Hedyotidis diffusae, a rhizome of Rhizoma Bistortae, a rhizome of Rhizoma Polygoni Cuspidati, and a ripe fruit of Fructus Schisandrae.
- 30. The method according to claim 29, said pharmaceutical composition further comprising aqueous extracts of a rhizome of Rhizoma Menispermi, a root of Radix Scutellariae, a bovine biliary powder, a tuber of Radix Curcumae, a ripe fruit of Fructus Crataegi, and a root of Radix Notoginseng.
- 31. The method according to claim 30, said pharmaceutical composition further comprising aqueous extracts of a ripe fruit of Fructus Lycii, a root of Radix Ginseng Rubra, a root of Radix Scorphulariae, a root of Radix Angelicae sinensis, and a root of Radix Astragali.
- 32. The method according to claim 29, wherein said pharmaceutical composition is administered orally or intravenously, or is concurrently administered orally and intravenously.
- 33. The method according to claim 29, wherein said lamivudine drug resistance is caused by a development of lamivudine-resistant hepatitis B virus (HBV) strains in patients.
RELATED INVENTION
[0001] This application claims the priority of U.S. Provisional Application Serial No. 60/327,002, filed on Oct. 5, 2001, and No. 60/331,257, filed on Nov. 13, 2001, which are herein incorporated by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60327002 |
Oct 2001 |
US |
|
60331257 |
Nov 2001 |
US |